← All trials
NCT04818281
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 27, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- Mar 31, 2022
- First posted
- Mar 26, 2021
- Last posted
- Jul 13, 2021
- Enrollment
- 36
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bilkent UniversityLead sponsor
- The Scientific and Technological Research Council of TurkeySponsor investigator
- The Scientific and Technological Research Council of TurkeyCollaborator
- MonitorCROCollaborator
- Nobel PharmaceuticalsCollaborator
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.